18,19 In patients with ischemic stroke treated with thrombolytic tPA, there is a highly significant positive correlation between hemorrhagic transformation and the plasma concentrations of PDGF-CC. 20 In addition, a phase 2 clinical trial in patients treated with intravenous tPA for ischemic stroke established that inhibition of PDGFRα signaling with the antagonist imatinib is safe and tolerable and may reduce neurologic disability in patients treated with thrombolysis after ischemic stroke. 21 A randomized phase 3 clinical trial is underway (registered at ClinicalTrials.gov as # NCT03639922 ).
← all excerpts
Thrombolytic tPA-induced hemorrhagic transformation of ischemic stroke is mediated by PKCβ phosphorylation of occludin.
1
—
—